Covid19 Clinical Trial
Official title:
Immune Response to Anti COVID-19 Vaccine in Immunocompromised Patients: a Cohort Study
NCT number | NCT04888793 |
Other study ID # | 210405014 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | May 12, 2021 |
Est. completion date | November 1, 2021 |
Verified date | May 2021 |
Source | Pontificia Universidad Catolica de Chile |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Despite COVID-19 pandemic having started more than one year ago, there are still limited treatment options for these patients, and over 145 million cases and 3 millions deaths have ensued worldwide. Fortunately, SARSCoV2 vaccines have been developed at an unprecedented pace. While the vaccination programs are still ongoing, early reports on efficacy are mainly centered on healthy population. In Chile most people have received the inactivated Coronavac vaccine. Data on the immune response after vaccination in immunocompromised patients is lacking. Therefore, this study aims to evaluate the immune response after Coronavac vaccine in 5 cohorts of immunocompromised patients and healthy controls. We will include patients with cancer, HIV, solid organ transplant and patients receiving immunomodulatory agents for rheumatic diseases.
Status | Completed |
Enrollment | 260 |
Est. completion date | November 1, 2021 |
Est. primary completion date | September 1, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | General Inclusion Criteria: - Eastern Cooperative Oncology Group < 3 - Vaccination with 2 doses of Coronavac vaccine General Exclusion Criteria: - Previous SARS-CoV-2 infection - Vaccination with Coronavac more than 12 weeks before informed consent - Intravenous immunoglobulin therapy 60 days before informed consent - Any condition, that could interfere with the participant's participation during the study in the opinion of the treating investigator. Cancer Cohort Inclusion Criteria: - Diagnosis of cancer in the previous 5 years (consistent biopsy is required). - Life expectancy more than 12 weeks Exclusion Criteria: - Bone marrow transplant, solid organ recipient, HIV, immunosuppressant treatment for other condition. Bone Marrow Transplant Cohort Inclusion Criteria: - Bone marrow transplant between January 2019 and December 2020 Exclusion Criteria: - Other cancer diagnosis during the last 5 years, solid organ recipient, HIV, immunosuppressant treatment for other condition. Solid Organ Recipient Cohort: Inclusion Criteria: - Liver, kidney or heart transplant between January 2019 and December 2020 - Active immunosuppressant treatment Exclusion Criteria: - Cancer diagnosis during the last 5 years, bone marrow transplant, immunosuppressant treatment for other condition, HIV HIV Cohort: Inclusion Criteria: - CD4 <= 500 cels/mm3 documented one year before study enrollment - Active antiretroviral therapy - Viral load < 200 copies/ml Exclusion Criteria: - Cancer diagnosis during the last 5 years, bone marrow transplant or solid organ recipient, immunosuppressant treatment. Rheumatic Disease Cohort Inclusion Criteria: - Diagnosis of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, relapsing polychondritis, Behcet disease or juvenile idiopathic arthritis - Chronic immunomodulatory treatment with anti-TNF, anti-IL6 or anti-IL17 agents Exclusion Criteria: - Treatment with more than one biological agent. - Cancer diagnosis during the last 5 years, bone marrow transplant or solid organ recipient, HIV diagnosis. |
Country | Name | City | State |
---|---|---|---|
Chile | Red de Salud UC Christus | Santiago |
Lead Sponsor | Collaborator |
---|---|
Pontificia Universidad Catolica de Chile |
Chile,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of positive neutralizing antibodies 8 to12 weeks after Coronavac vaccine | 8 to12 weeks after Coronavac vaccine | ||
Secondary | Neutralizing geometric mean titers 8 to12 weeks after Coronavac vaccine | 8 to12 weeks after Coronavac vaccine |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |